For instance, elevated TRIB1 expression is able to induce AML via activation of ERK and degradation of C/EBPα; TRIB3 regulates MAPK- and TGF-β-mediated Notch activation to promote cancer progression in breast cancer cells and promotes APL progression via interacting with and inhibiting degradation of oncoprotein PML-RARα [32, 33]; TRIB2 is also reported to contribute to acute myeloid leukemia (AML) and hematopoietic development [34]. Here, TRIB3 is linked to breast carcinoma.